{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T11:00:08Z","timestamp":1775818808603,"version":"3.50.1"},"reference-count":78,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DDDT"],"DOI":"10.2147\/dddt.s240861","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T21:32:30Z","timestamp":1620682350000},"page":"1993-2004","source":"Crossref","is-referenced-by-count":28,"title":["An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis"],"prefix":"10.2147","volume":"Volume 15","author":[{"given":"Marzia","family":"Fronza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jnr","given":"Lorena","family":"Lorefice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Frau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3878-8820","authenticated-orcid":true,"given":"Eleonora","family":"Cocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"s53","DOI":"10.7861\/clinmedicine.16-6-s53","volume":"16","author":"Doshi","year":"2016","journal-title":"Clin Med (Lond)"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/WCO.0000000000000622","volume":"31","author":"Oh","year":"2018","journal-title":"Curr Opin Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/intimm\/dxz037","volume":"31","author":"Obinata","year":"2019","journal-title":"Int Immunol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s13311-017-0565-4","volume":"14","author":"Chaudhry","year":"2017","journal-title":"Neurotherapeutics"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1080\/14656566.2018.1540592","volume":"19","author":"Rasche","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.4049\/jimmunol.160.10.5037","volume":"160","author":"Chiba","year":"1998","journal-title":"J Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3390\/biomedicines8070227","volume":"8","author":"Cohan","year":"2020","journal-title":"Biomedicines"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa052643","volume":"355","author":"Kappos","year":"2006","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1096\/fj.06-7420com","volume":"21","author":"Novgorodov","year":"2007","journal-title":"FASEB J"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1523\/JNEUROSCI.4645-04.2005","volume":"25","author":"Jaillard","year":"2005","journal-title":"J Neurosci"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/1742-2094-9-133","volume":"9","author":"Van Doorn","year":"2012","journal-title":"J Neuroinflammation"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"6377","DOI":"10.1016\/j.bmcl.2013.09.058","volume":"23","author":"Urbano","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00415-013-7115-8","volume":"261","author":"Gold","year":"2014","journal-title":"J Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/j.1476-5381.2012.02061.x","volume":"167","author":"Gergely","year":"2012","journal-title":"Br J Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/S1474-4422(13)70102-9","volume":"12","author":"Selmaj","year":"2013","journal-title":"Lancet Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1001\/jamaneurol.2016.1451","volume":"73","author":"Kappos","year":"2016","journal-title":"JAMA Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/14656566.2018.1551363","volume":"20","author":"Dumitrescu","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"ref19","unstructured":"U.S. Food and Drug Administration (FDA). FDA approves new oral drug to treat multiple sclerosis; 2021. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-oral-drug-treat-multiple-sclerosis. Accessed March 26, 2019."},{"key":"ref20","unstructured":"European Medicines Agency (EMA). Mayzent EPAR; 2021. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mayzent. Accessed November 12, 2019."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1136\/jnnp-2013-307282","volume":"85","author":"Olsson","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.0405","author":"Kappos","year":"2021","journal-title":"JAMA Neurol"},{"key":"ref23","unstructured":"European Medicines Agency (EMA). Ponvory; 2021. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/summaries-opinion\/ponvory. Accessed March 25, 2021."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1111\/bph.13476","volume":"173","author":"Scott","year":"2016","journal-title":"Br J Pharmacol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1002\/jcph.887","volume":"57","author":"Tran","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"ref26","unstructured":"ECTRIMS Online Library. Taylor Meadows K Ozanimod (RPC1063) is potentially neuroprotective through direct CNS effects. 10\/27\/17; 200838; P118310\/27\/17; 200838; P1183. Available from: https:\/\/onlinelibrary.ectrims-congress.eu\/ectrims\/2017\/ACTRIMS-ECTRIMS2017\/200838\/kristen.r.taylor.meadows.ozanimod.28rpc106329.is.potentially.neuroprotective.html. Accessed April 23, 2021."},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Taylor Meadows K, Scott F, Villescaz C, et al. Ozanimod (RPC1063) reduces the plasma biomarker neurofilament light chain in preclinical rodent models of multiple sclerosis. ECTRIMS Online Library; 2021. Available from: https:\/\/onlinelibrary.ectrims-congress.eu\/ectrims\/2017\/ACTRIMS-ECTRIMS2017\/199629\/kristen.r.taylor.meadows.ozanimod.(rpc1063).reduces.the.plasma.biomarker.html. Accessed April 23, 2021.","DOI":"10.26226\/morressier.59a3e8b6d462b8028d895019"},{"key":"ref28","unstructured":"Taylor Meadows K Ozanimod (RPC1063) is potentially neuroprotective through direct CNS effects. ECTRIMS online library; 2021. Available from: https:\/\/onlinelibrary.ectrims-congress.eu\/ectrims\/2017\/ACTRIMS-ECTRIMS2017\/200838\/kristen.r.taylor.meadows.ozanimod.28rpc106329.is.potentially.neuroprotective.html. Accessed April 23, 2021."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.3390\/cells9051290","volume":"9","author":"Musella","year":"2020","journal-title":"Cells"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/WCO.0000000000000700","volume":"32","author":"Cree","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"ref31","unstructured":"Celgene Corporation. Zeposia (ozanimod) capsules: US prescription information 2020; 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209899s000lbl.pdf. Accessed April 23, 2021."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/cpdd.409","volume":"7","author":"Tran","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref33","unstructured":"ZEPOSIA (Ozanimod) (Package Insert). Celgene Corporation: summit, NJ, USA; 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209899s000lbl.pdf. Accessed April 23, 2021."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e839","DOI":"10.1212\/NXI.0000000000000839","volume":"7","author":"Harris","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S1474-4422(16)00018-1","volume":"15","author":"Cohen","year":"2016","journal-title":"Lancet Neurol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"102673","DOI":"10.1016\/j.msard.2020.102673","volume":"48","author":"DeLuca","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"ref39","unstructured":"ECTRIMS Online Library. Steinman L. 09\/12\/19; 278233; P1031. Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: results from the DAYBREAK Open-Label Extension Study; 2021. Available from: https:\/\/onlinelibrary.ectrims-congress.eu\/ectrims\/2019\/stockholm\/278233\/lawrence.steinman.long-term.safety.and.efficacy.of.ozanimod.in.relapsing.html. Accessed April 23, 2021."},{"key":"ref40","unstructured":"The ENLIGHTEN study; 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03261453. Accessed April 23, 2021."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2217\/cer-2019-0169","volume":"9","author":"Swallow","year":"2020","journal-title":"J Comp Eff Res"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05049-w","author":"Tong","year":"2021","journal-title":"Neurol Sci"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1002\/sim.1875","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/S1474-4422(16)30192-2","volume":"15","author":"Kappos","year":"2016","journal-title":"Lancet Neurol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1177\/1352458517728343","volume":"24","author":"Kappos","year":"2018","journal-title":"Mult Scler"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1177\/1352458512454773","volume":"18","author":"Hakiki","year":"2012","journal-title":"Mult Scler"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jneuroim.2015.03.022","volume":"282","author":"Berger","year":"2015","journal-title":"J Neuroimmunol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00415-012-6744-7","volume":"260","author":"Ghezzi","year":"2013","journal-title":"J Neurol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1001\/jamaneurol.2016.0826","volume":"73","author":"Hatcher","year":"2016","journal-title":"JAMA Neurol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1111\/ene.13694","volume":"25","author":"Frau","year":"2018","journal-title":"Eur J Neurol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"e0124923","DOI":"10.1371\/journal.pone.0124923","volume":"10","author":"Song","year":"2015","journal-title":"PLoS One"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"e129685","DOI":"10.1016\/j.molstruc.2020.129685","volume":"1227","author":"Al-Zaqri","year":"2021","journal-title":"J Mol Struc"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"e0193236","DOI":"10.1371\/journal.pone.0193236","volume":"13","author":"Taylor Meadows","year":"2018","journal-title":"PLoS One"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","volume":"374","author":"Sandborn","year":"2016","journal-title":"N Engl J Med"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"jjab012","DOI":"10.1093\/ecco-jcc\/jjab012","author":"Sandborn","year":"2021","journal-title":"J Crohns Colitis"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S2468-1253(20)30188-6","volume":"5","author":"Feagan","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s40265-020-01319-7","volume":"80","author":"Lamb","year":"2020","journal-title":"Drugs"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fphar.2019.00212","volume":"10","author":"P\u00e9rez-Jeldres","year":"2019","journal-title":"Front Pharmacol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.neuropharm.2016.11.006","volume":"113","author":"O\u2019Sullivan","year":"2017","journal-title":"Neuropharmacology"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1007\/s13311-016-0462-2","volume":"13","author":"Potenza","year":"2016","journal-title":"Neurotherapeutics"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"14230","DOI":"10.1073\/pnas.1206093109","volume":"109","author":"Deogracias","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3389\/fneur.2016.00139","author":"Li","year":"2016","journal-title":"Front Neurol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/neuonc\/nos005","volume":"14","author":"Estrada-Bernal","year":"2012","journal-title":"Neuro Oncol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1093\/hmg\/ddt615","volume":"23","author":"Di Pardo","year":"2014","journal-title":"Hum Mol Genet"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.pbb.2012.08.025","volume":"103","author":"Gao","year":"2012","journal-title":"Pharmacol Biochem Behav"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s40263-020-00756-y","volume":"34","author":"Zheng","year":"2020","journal-title":"CNS Drugs"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"102800","DOI":"10.1016\/j.msard.2021.102800","volume":"50","author":"Sharifian-Dorche","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1177\/1352458520942198","volume":"26","author":"Loonstra","year":"2020","journal-title":"Mult Scler"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"102414","DOI":"10.1016\/j.msard.2020.102414","volume":"45","author":"Mallucci","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"117011","DOI":"10.1016\/j.jns.2020.117011","volume":"416","author":"Bollo","year":"2020","journal-title":"J Neurol Sci"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"e783","DOI":"10.1212\/NXI.0000000000000783","volume":"7","author":"Bowen","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"e753","DOI":"10.1212\/NXI.0000000000000753","volume":"7","author":"Barzegar","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"102180","DOI":"10.1016\/j.msard.2020.102180","volume":"42","author":"Foerch","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/jmv.26279","volume":"93","author":"Gomez-Mayordomo","year":"2020","journal-title":"J Med Virol"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"e835","DOI":"10.1212\/NXI.0000000000000835","volume":"7","author":"Parrotta","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/ana.26028","volume":"89","author":"Sormani","year":"2021","journal-title":"Ann Neurol"},{"key":"ref77","unstructured":"U.S. Food and Drug Administration (FDA). Drug Trials Snapshots: ZEPOSIA; 2021. Available from: https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/drug-trials-snapshots-zeposia. Accessed April 23, 2021."},{"key":"ref78","unstructured":"European Medicines Agency (EMA). Zeposia; 2021. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zeposia. Accessed April 23, 2021."}],"container-title":["Drug Design, Development and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=69289","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=69289","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T15:02:52Z","timestamp":1699023772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/an-overview-of-the-efficacy-and-safety-of-ozanimod-for-the-treatment-o-peer-reviewed-fulltext-article-DDDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":78,"URL":"https:\/\/doi.org\/10.2147\/dddt.s240861","relation":{},"ISSN":["1177-8881"],"issn-type":[{"value":"1177-8881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}